Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.
Oosting SF, van der Veldt AAM, Fehrmann RSN, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, de Wilt F, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CACM, Rots NY, van Baarle D, Haanen JBAG, de Vries EGE. Oosting SF, et al. Among authors: jalving m. Lancet Oncol. 2022 Jul;23(7):833-835. doi: 10.1016/S1470-2045(22)00203-0. Epub 2022 Apr 25. Lancet Oncol. 2022. PMID: 35483383 Free PMC article. No abstract available.
Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.
de Heer EC, Zois CE, Bridges E, van der Vegt B, Sheldon H, Veldman WA, Zwager MC, van der Sluis T, Haider S, Morita T, Baba O, Schröder CP, de Jong S, Harris AL, Jalving M. de Heer EC, et al. Among authors: jalving m. J Exp Clin Cancer Res. 2023 Jun 6;42(1):143. doi: 10.1186/s13046-023-02715-z. J Exp Clin Cancer Res. 2023. PMID: 37280675 Free PMC article.
Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer.
de Heer EC, Zois CE, Bridges E, van der Vegt B, Sheldon H, Veldman WA, Zwager MC, van der Sluis T, Haider S, Morita T, Baba O, Schröder CP, de Jong S, Harris AL, Jalving M. de Heer EC, et al. Among authors: jalving m. J Exp Clin Cancer Res. 2023 Aug 28;42(1):220. doi: 10.1186/s13046-023-02800-3. J Exp Clin Cancer Res. 2023. PMID: 37635223 Free PMC article. No abstract available.
Molecular imaging in ovarian cancer.
Reyners AK, Broekman KE, Glaudemans AW, Brouwers AH, Arts HJ, van der Zee AG, de Vries EG, Jalving M. Reyners AK, et al. Among authors: jalving m. Ann Oncol. 2016 Apr;27 Suppl 1:i23-i29. doi: 10.1093/annonc/mdw091. Ann Oncol. 2016. PMID: 27141066 Free article. Review.
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.
de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel FWPJ, Mutsaers PGNJ, van Diemen NGJ, Visser OJ, Oomen-de Hoop E, Bloemendal HJ, van Laarhoven HWM, Hendriks LEL, Haanen JBAG, de Vries EGE, Dingemans AC, van der Veldt AAM; DOCC Investigators. de Joode K, et al. Eur J Cancer. 2020 Dec;141:171-184. doi: 10.1016/j.ejca.2020.09.027. Epub 2020 Oct 7. Eur J Cancer. 2020. PMID: 33161241 Free PMC article.
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM, Timens W, Elias SG, Hospers GAP, Groen HJM, Uyterlinde W, van der Hiel B, Haanen JB, de Groot DJA, Jalving M, de Vries EGE. Kok IC, et al. Among authors: jalving m. Ann Oncol. 2022 Jan;33(1):80-88. doi: 10.1016/j.annonc.2021.10.213. Epub 2021 Nov 1. Ann Oncol. 2022. PMID: 34736925 Free article.
103 results